Preparing The World For Influenza Pandemic, Industry Role Key, Says WHO 12/04/2011 by Catherine Saez, Intellectual Property Watch 6 Comments An influenza pandemic is like the sword of Damocles over the world, and the recent H1N1 pandemic showed that the global response was inadequate, said the co-chairs of a World Health Organization group working on influenza pandemic preparedness meeting this week.
WHO Experts On R&D Financing Aim To Find Solutions, With Short Timeline 08/04/2011 by Catherine Saez, Intellectual Property Watch 3 Comments The search for innovative solutions to engage research and development of health products for diseases that particularly affect developing countries is the core mission of a World Health Organization working group that met this week in a special mostly open session. The group of experts will assess proposals and deliver its recommendations next year.
Financial Transaction Tax: A Resource For WHO Global Strategy And Plan of Action 07/04/2011 by Intellectual Property Watch 1 Comment A recent European Parliament resolution on a European Financial Transaction Tax could represent an important resource for a WHO-led initiative to find sustainable financing for research into diseases afflicting poor populations.
WHO Experts To Analyse R&D Financing, Focus On Poor Country Diseases 31/03/2011 by Catherine Saez, Intellectual Property Watch 2 Comments The World Health Organization expert working group tasked with studying proposals on financing and coordinating research and development for diseases that disproportionately affect developing countries will meet next week. The working group’s path is not easy as it follows a predecessor group that sustained allegations of conflict of interest and lack of transparency.
Registration Still Open For WHO Sessions On R&D Financing 29/03/2011 by Intellectual Property Watch Leave a Comment The expert group at the World Health Organization looking for ideas to fund research into diseases disproportionately affecting poor populations will open up its first meeting next week to public input. Participants can register for the open sessions until Monday, 4 April at noon. Proposals for a presentation to the group are due by Friday, 1 April at noon.
Committee Nears Final Review Of WHO Performance On H1N1 Pandemic 29/03/2011 by Catherine Saez, Intellectual Property Watch 4 Comments The committee reviewing the World Health Organization’s response to the 2009 H1N1 pandemic and whether the international organisation was unduly influenced by the pharmaceutical industry in its response is working this week to formulate its final report.
Pharma Industry Seeks To Bring A Fresh Face To Public Health Policy 23/03/2011 by William New, Intellectual Property Watch Leave a Comment The research-based pharmaceutical industry is working to bring a fresh face to the international public health policy arena in Geneva, most recently through a new initiative on technology transfer. Working through the industry’s Geneva-based trade association, the effort to be seen in a more positive light comes after years of doubts about the transparency of its involvement in these issues and could change the tenor of international negotiations.
UN Agencies Encourage Use Of WTO Measures To Lower HIV Medicines Costs 15/03/2011 by William New, Intellectual Property Watch 3 Comments Three United Nations agencies have joined together to explain to their member countries the little-understood but hard-won flexibilities to applying stiff international intellectual property rules. The focus of the new policy brief is on improving access to HIV treatment, and it offers a series of actions for governments and international organisations.
Medicines Patent Pool Aims To Increase Access To HIV Drugs In Developing Countries 10/03/2011 by Tavengwa Runyowa for Intellectual Property Watch 5 Comments The newly created Medicines Patent Pool promises to increase access to HIV/AIDS medications in developing markets. Based in Geneva, Switzerland, the pool operates a scheme in which pharmaceutical patent holders voluntarily licence their drugs to generic manufacturers who then produce more affordable versions for patients in poorer countries
WHO Working Group Gives Guidelines To Fight Bad Medicines; IMPACT In Exile 03/03/2011 by Catherine Saez, Intellectual Property Watch 4 Comments After three days of intense negotiations on the role of the World Health Organization in the fight against low standard or falsified medicines, delegates provided recommendations for the UN agency. A subject of dissent was the relationship between the WHO and its taskforce against counterfeit medicines, with some countries calling for a suspension of the taskforce’s work, though in the end no consensus was found.